The Nephrologist’s Role in the Collaborative Multi-Specialist Network Taking Care of Patients with Diabetes on Maintenance Hemodialysis: An Overview
Open Access
- 10 March 2022
- journal article
- research article
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 11 (6) , 1521
Abstract
Diabetes mellitus is the leading cause of renal failure in incident dialysis patients in several countries around the world. The quality of life for patients with diabetes in maintenance hemodialysis (HD) treatment is in general poor due to disease complications. Nephrologists have to cope with all these problems because of the “total care model” and strive to improve their patients’ outcome. In this review, an updated overview of the aspects the nephrologist must face in the management of these patients is reported. The conventional marker of glycemic control, hemoglobin A1c (HbA1c), is unreliable. HD itself may be responsible for dangerous hypoglycemic events. New methods of glucose control could be used even during dialysis, such as a continuous glucose monitoring (CGM) device. The pharmacological control of diabetes is another complex topic. Because of the risk of hypoglycemia, insulin and other medications used to treat diabetes may need dose adjustment. The new class of antidiabetic drugs dipeptidyl peptidase 4 (DPP-4) inhibitors can safely be used in non-insulin-dependent end-stage renal disease (ESRD) patients. Nephrologists should take care to improve the hemodynamic tolerance to HD treatment, frequently compromised by the high level of ultrafiltration needed to counter high interdialytic weight gain. Kidney and pancreas transplantation, in selected patients with diabetes, is the best therapy and is the only approach able to free patients from both dialysis and insulin therapy.Keywords
This publication has 95 references indexed in Scilit:
- Absolute Blood Volume in Hemodialysis Patients: Why Is It Relevant, and How to Measure ItBlood Purification, 2013
- RETRACTED ARTICLE: Risk factors for increased left ventricular hypertrophy in patients with chronic kidney diseaseClinical and Experimental Nephrology, 2013
- Glycemic Control and Cardiovascular Mortality in Hemodialysis Patients With DiabetesDiabetes, 2012
- Association of HbA1c Values with Mortality and Cardiovascular Events in Diabetic Dialysis Patients. The INVOR Study and Review of the LiteraturePLOS ONE, 2011
- Rapid fluid removal during dialysis is associated with cardiovascular morbidity and mortalityKidney International, 2011
- Hemofiltration and Hemodiafiltration Reduce Intradialytic Hypotension in ESRDJournal of the American Society of Nephrology, 2010
- Assessing Glycemic Control in Maintenance Hemodialysis Patients With Type 2 DiabetesDiabetes Care, 2009
- Effect of acetate-free biofiltration with a potassium-profiled dialysate on the control of cardiac arrhythmias in patients at risk: A pilot studyHemodialysis International, 2008
- Glycated Albumin Is a Better Glycemic Indicator than Glycated Hemoglobin Values in Hemodialysis Patients with DiabetesJournal of the American Society of Nephrology, 2007
- Hemodialyzed type I and type II diabetic patients in the US: Characteristics, glycemic control, and survivalKidney International, 2006